Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · InspireMD, Inc. (NSPR)

InspireMD amends warrants, cutting exercise price to $0.7674; up to $11 million possible

Mixed Impact 3 of 5 financing Written later

InspireMD amended some of its outstanding Series J and Series K warrants with certain holders, lowering the exercise price on the affected shares to $0.7674 and tying their expiration to the anticipated FDA approval of CGuard Prime 80 cm. The company says that if the warrants are exercised in full, they could bring in up to $11 million in gross proceeds, which it expects to help fund the product launch, while existing shareholders face the potential dilution that would follow.

Key points

  • Amendments cover 50% of the Series J warrant shares and all Series K warrant shares held by participating holders, with the rest of the Series J shares unchanged at $1.3827.
  • New termination date is 5:00 p.m. Eastern on the earlier of May 15, 2028 or 20 trading days after the company announces FDA approval of CGuard Prime 80 cm, which it expects in Q4 2026.
  • The press release says up to $11 million in gross proceeds if the warrants are exercised in full; no new warrants were issued.
  • Some participating warrant holders are members of the company's board of directors.

The filing

CompanyInspireMD, Inc. (NSPR)
Form8-K, current report
Filed with the SECSep 21, 2026, 9:12 AM ET
Accession number0001493152-26-043488

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.